# Reinhard Dummer

Source: https://onco.cc/people/reinhard-dummer/  
OnCo record `reinhard-dummer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies.

## Summary

Reinhard Dummer was principal investigator of COLUMBUS, which established encorafenib plus binimetinib in BRAF-mutant melanoma, and led the first randomised neoadjuvant trial of the oncolytic virus talimogene laherparepvec. He has led ESMO melanoma guidelines and trials in cutaneous T-cell lymphoma and Merkel cell carcinoma, and heads the skin cancer centre at University Hospital Zurich.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; targeted-therapy; switzerland
- Role: Professor of Dermatology and Vice Chairman, Department of Dermatology, University Hospital Zurich
- Specialisms: Melanoma; BRAF/MEK targeted therapy; Oncolytic virus therapy; Cutaneous lymphoma

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Dummer%20R%5BAuthor%5D%20melanoma%20encorafenib%20OR%20talimogene

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BRAF](https://onco.cc/targets/braf/)
- drugs: [Encorafenib](https://onco.cc/drugs/encorafenib/), [Talimogene laherparepvec](https://onco.cc/drugs/talimogene-laherparepvec/)
- institutions: [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/)
- trials: [BOLT](https://onco.cc/trials/bolt/), [COLUMBUS](https://onco.cc/trials/columbus/), [FOCUS](https://onco.cc/trials/nct02678572/)

---
JSON: https://onco.cc/api/v1/entities/reinhard-dummer.json